On February 28, 2019 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported an upcoming poster presentation at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place from March 29 – April 3, 2019 in Atlanta, GA (Press release, Bio-Path Holdings, FEB 28, 2019, View Source [SID1234533906]).
Details for the poster presentation are as follows:
Date: Wednesday, April 3, 2019
Presentation Time: 8:00 am – 12:00 pm Eastern Time
Location: Georgia World Congress Center, Exhibit Hall B
Session: Gene- and Vector-Based Therapy, Poster Section 12
Title: "BP1003, A Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor"